Schedule of Common Stock Computation of Diluted Net Loss Per Share of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net loss attributable to Oncocyte Corporation	$ (6,489)	$ (9,333)	$ (11,789)	$ (27,924)
Accretion of Series A redeemable convertible preferred stock	(198)	(294)	(621)	(294)
Deemed dividend on Series A redeemable convertible preferred stock			(118)
Net loss attributable to common stockholders - Basic	(6,687)	(9,627)	(12,528)	(28,218)
Net loss attributable to common stockholders - diluted	$ (6,687)	$ (9,627)	$ (12,528)	$ (28,218)
Weighted average number of shares outstanding, basic	8,256	5,931	7,446	5,408
Weighted average number of shares outstanding, diluted	8,256	5,931	7,446	5,408
Basic net loss per common share	$ (0.81)	$ (1.62)	$ (1.68)	$ (5.22)
Earnings Per Share, diluted	$ (0.81)	$ (1.62)	$ (1.68)	$ (5.22)
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share	1,331,000	1,570,000	1,331,000	1,570,000
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share	501,000	717,000	501,000	717,000
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share	5,000	29,000	5,000	29,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share	820,000	820,000	820,000	820,000
Series A Redeemable Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive potential common shares excluded from the computation of diluted net loss per common share	5,000	4,000	5,000	4,000